{{scheme.chgp}}%
{{scheme.chgp}}%
No Matches Found
{{scheme.chgp}}%
No Matches Found
No Matches Found
Sanara MedTech, Inc.
Sanara MedTech Hits New 52-Week Low at $19.06 Amid Ongoing Struggles
Sanara MedTech, Inc. has reached a new 52-week low, reflecting a significant decline in its stock price over the past year. The company, with a market capitalization of USD 318 million, has faced financial difficulties, including consecutive quarterly losses and a negative return on equity. Its financial metrics indicate ongoing challenges in the biotechnology sector.
Sanara MedTech Hits 52-Week Low at $19.10 Amid Ongoing Struggles
Sanara MedTech, Inc. has reached a new 52-week low, reflecting a difficult year marked by a significant stock price decline. The company, with a market capitalization of USD 318 million, has faced ongoing financial challenges, including consecutive quarterly losses and negative returns on equity and capital employed.
Sanara MedTech Hits 52-Week Low at USD 21.07 Amid Ongoing Struggles
Sanara MedTech, Inc. has reached a new 52-week low, reflecting a difficult year marked by a significant stock price decline. The company, with a market capitalization of USD 318 million, has faced ongoing financial challenges, including consecutive quarterly losses and a negative return on equity, raising concerns about its operational efficiency.
Sanara MedTech Forms Golden Cross, Signaling Potential Bullish Breakout
Sanara MedTech, Inc. has recently experienced a Golden Cross, indicating a potential shift in momentum. Despite a recent decline and mixed technical indicators, the stock has shown growth over three and five years, suggesting possible recovery opportunities for investors as market reactions unfold.
Is Sanara MedTech, Inc. technically bullish or bearish?
As of September 11, 2025, Sanara MedTech, Inc. shows a neutral trend with mixed signals, as the weekly MACD is bullish while the monthly MACD is bearish, and the stock has underperformed the S&P 500 across all time frames.
Is Sanara MedTech, Inc. overvalued or undervalued?
As of February 11, 2019, Sanara MedTech, Inc. is considered overvalued with a high Price to Book Value of 7.15, negative EV to EBIT and EV to EBITDA ratios, and poor returns on capital and equity, indicating a risky investment compared to its peers.
Is Sanara MedTech, Inc. overvalued or undervalued?
As of February 11, 2019, Sanara MedTech, Inc. is considered overvalued and risky due to poor financial metrics and stock performance, with a Price to Book Value of 7.15 and negative earnings ratios compared to its peers.
Is Sanara MedTech, Inc. technically bullish or bearish?
As of May 19, 2025, Sanara MedTech, Inc. is in a bearish trend, supported by bearish signals from the MACD, moving averages, and Bollinger Bands, while the KST shows mixed signals and the RSI and OBV reinforce the bearish outlook.
Who are in the management team of Sanara MedTech, Inc.?
As of March 2022, the management team of Sanara MedTech, Inc. includes Executive Chairman Ronald Nixon, Principal Executive Officer J Carmena, and Directors Robert DeSutter, Sara Ortwein, Ann Salamone, and Kenneth Thorpe. They oversee the company's strategic direction and operations.
What does Sanara MedTech, Inc. do?
Sanara MedTech, Inc. distributes collagen-based wound care products and operates in the Pharmaceuticals & Biotechnology industry. As of March 2025, it reported net sales of $23 million and a net loss of $4 million, with a market cap of $247.26 million.
How big is Sanara MedTech, Inc.?
As of Jun 18, Sanara MedTech, Inc. has a market capitalization of 247.26 million and reported net sales of 91.57 million with a net profit of -11.64 million over the last four quarters. Shareholder's funds are 39.40 million, and total assets are valued at 88.09 million.
{{list.post_title}}
{{list.post_excerpt}}
{{list.post_title}}
{{list.post_excerpt}}
